Ipca Laboratories enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


48,977	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1,071	1,071	931	767	1,581
1,460	1,460	1,440	1,395	73.3
704	704	1,302	1,388	1,458
50,070	—	—	—	—
−367	−367	371	620	−124
₹1,973.61	—	—	—	—

10,228	10,228	9,690	9,115	7,373
6.9%	6.9%	13.4%	15.2%	19.8%
0.01×	—	—	—	—

4.94×	—	—	—	—
22.44×	—	—	—	—
27.77×	—	—	—	—
102.25×	—	—	—	—
10,126	9,646	8,940	7,705	6,244
2,232	1,979	1,726	1,321	927
1,803	1,560	1,328	964	665
—	1,142	1,321	945	806
490	490	546	533	311
—	471	524	484	298
—	652	776	411	494

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

IPCALAB₹1,930.50

Ipca Laboratories Ltd.

· Pharma & Health

₹ CrorePeersTORNTPHARM ALKEM JBCHEPHARM ABBOTINDIA AJANTPHARM ANTHEM GLAXO MEDANTAMcap ₹48,977 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	48,976.8
- Cash, Equiv & ST Investments	1,581.2	767.3	930.6	1,070.5	1,070.5
+ Minority Interest	73.3	1,394.8	1,439.8	1,460.3	1,460.3
+ Total Debt	1,457.5	1,387.5	1,301.7	703.9	703.9
Enterprise Value	—	—	—	—	50,070.4
Net Debt (memo)	-123.6	620.2	371.1	-366.6	-366.6
EV per Share	—	—	—	—	1,973.61

Total Capital	7,372.9	9,114.5	9,690.0	10,228.0	10,228.0
Total Debt/Total Capital	19.77	15.22	13.43	6.88	6.88
Total Debt/EV	—	—	—	—	0.01

EV/Sales	—	—	—	—	4.94
EV/EBITDA	—	—	—	—	22.44
EV/EBIT	—	—	—	—	27.77
EV/Free Cash Flow	—	—	—	—	102.25
Reference Items — Trailing FY Values
Sales	6,244.3	7,705.0	8,939.6	9,646.3	10,125.6
EBITDA	926.8	1,321.2	1,726.1	1,978.6	2,231.7
EBIT	665.2	963.9	1,328.3	1,560.4	1,802.8
Operating Cash Flow	805.8	944.7	1,321.3	1,142.0	—
Free Cash Flow	311.3	533.4	545.8	489.7	489.7
FCFF (free cash flow to the firm)	297.8	484.4	524.5	471.4	—
Capital Expenditure	494.5	411.3	775.5	652.3	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.